EPSI began operating in the territories in 2008. Conducting clinical trials in Hong Kong is an excellent alternative to China, where setting up operations can be daunting despite its attractions, and China is projected to become the largest pharmaceutical market in 2020. Hong Kong has many research hospitals already accredited in China, and boasts excellent infrastructure. New legislation in 2015 simplified the process for clinical trials. This legislation eliminates the requirement for product samples and extends the regulatory validity approval period to five years from the previous two.
Health Expenditure per Capita
Source: Financing Global Health Database 2018
Life Expectancy at Birth
Source: The World Bank
Hong Kong: an attractive alternative to China for clinical trials
Complex rules and regulations can make conducting trials in mainland China a challenge. This is despite the fact its pharmaceutical market is the second largest in the world with an annual growth rate of 9.1% ...
Hong Kong's new efficiencies in regulatory approvals for clinical trials
In order to ensure the quality of clinical trials conducted in Hong Kong, it is mandatory to apply for a certificate before conducting any clinical trials in Hong Kong. All clinical trials conducted in Hong Kong must ...